Byungheon Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Byungheon Lee has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
Gowri Rangaswamy Gunassekaran
Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
14 shared publicationsSri Murugan Poongkavithai Vadevoo
Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
13 shared publicationsIn-San Kim
Biomedical Center, Korea Institute of Science and Technology, 5 Hwarang-ro 14 gil, Seongbuk-gu, Seoul, 02792, Republic of Korea; KU-KIST School, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea
10 shared publicationsLianhua Chi
Department of Biochemistry and Cell Biology, School Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu 41944, Republic of Korea
7 shared publicationsSmriti Gurung
Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
7 shared publicationsSoyoun Kim
Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
6 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
A Peptide Inhibitor of Lymphocyte Activation Gene-3 Interaction with Fibrinogen-like Protein 1 Synergizes with Programmed Death-Ligand 1 Blockade to Restore T Cell Activity and Inhibit Tumor Growth
The immune checkpoint lymphocyte activation gene-3 (LAG-3) interacts with major histocompatibility complex class II and fibrinogen-like protein 1 (FGL-1) to suppress T cell activity, contributing to resistance against immunotherapies such as programmed death-ligand 1 (PD-L1) blockade. This study aimed to identify LAG-3-binding peptides capable of disrupting these immunosuppressive interactions. Using a phage-displayed peptide library, we identified 2 candidate peptides, LAG3pep-1 and LAG3pep-2, that preferentially bound to LAG-3-expressing cells and recombinant LAG-3 protein. A LAG-3 D1 domain-blocking antibody competitively inhibited the peptide binding to LAG-3-expressing cells, confirming target specificity. Among the 2 peptides, LAG3pep-2 demonstrated higher binding affinity and greater stability toward LAG-3. These findings were further supported by structural modeling and all-atom simulation of the LAG-3 and peptide complexes and in silico mutational analysis. Functionally, LAG3pep-2 restored interleukin-2 secretion in T cells suppressed by tumor-derived FGL-1 more effectively than LAG3pep-1. Furthermore, LAG3pep-2 synergized with a PD-L1-blocking antibody to rescue T cell cytotoxicity and cytokine production in tumor cell co-culture assays. In vivo, systemic administration of LAG3pep-2 in combination with PD-L1 blockade significantly suppressed syngeneic tumor growth, enhanced anti-tumor immunity, and exhibited no observable systemic toxicity, outperforming either monotherapy. Collectively, these findings identify LAG3pep-2 as a peptide inhibitor of LAG-3 interaction with FGL-1 and a promising combinatorial agent to potentiate PD-L1-targeted cancer immunotherapies.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Open AccessA Peptide Inhibitor of Lymphocyte Activation Gene-3 Interaction with Fibrinogen-like Protein 1 Synergizes with Programmed Death-Ligand 1 Blockade to Restore T Cell Activity and Inhibit Tumor Growth
The immune checkpoint lymphocyte activation gene-3 (LAG-3) interacts with major histocompatibility complex class II and fibrinogen-like protein 1 (FGL-1) to suppress T cell activity, contributing to resistance against immunotherapies such as programmed death-ligand 1 (PD-L1) blockade. This study aimed to identify LAG-3-binding peptides capable of disrupting these immunosuppressive interactions. Using a phage-displayed peptide library, we identified 2 candidate peptides, LAG3pep-1 and LAG3pep-2, that preferentially bound to LAG-3-expressing cells and recombinant LAG-3 protein. A LAG-3 D1 domain-blocking antibody competitively inhibited the peptide binding to LAG-3-expressing cells, confirming target specificity. Among the 2 peptides, LAG3pep-2 demonstrated higher binding affinity and greater stability toward LAG-3. These findings were further supported by structural modeling and all-atom simulation of the LAG-3 and peptide complexes and in silico mutational analysis. Functionally, LAG3pep-2 restored interleukin-2 secretion in T cells suppressed by tumor-derived FGL-1 more effectively than LAG3pep-1. Furthermore, LAG3pep-2 synergized with a PD-L1-blocking antibody to rescue T cell cytotoxicity and cytokine production in tumor cell co-culture assays. In vivo, systemic administration of LAG3pep-2 in combination with PD-L1 blockade significantly suppressed syngeneic tumor growth, enhanced anti-tumor immunity, and exhibited no observable systemic toxicity, outperforming either monotherapy. Collectively, these findings identify LAG3pep-2 as a peptide inhibitor of LAG-3 interaction with FGL-1 and a promising combinatorial agent to potentiate PD-L1-targeted cancer immunotherapies.
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Mesothelin-Binding Peptide Inhibits Cell Migration and Enables Targeted Delivery of a Mitochondrial-Membrane-Damaging Peptide to Pancreatic Tumors
Mesothelin (MSLN) is up-regulated in many tumors, including pancreatic tumors, making it a promising therapeutic target. We used a phage-displayed peptide library to identify an MSLN-binding peptide. CTILWSLTC, synthesized in cyclic form (MSLNpep), was selected from the library. MSLNpep bound preferentially to MSLN-high versus MSLN-low cells, internalized efficiently, and bound recombinant MSLN more strongly than a control peptide. MSLNpep treatment reduced migration and invasion in MSLN-high tumor cells. To enable targeted cytotoxicity, we generated chimeras linking MSLNpep to L-form or D-form mitochondrial-membrane-damaging peptides (MSLNpep-KLA and MSLNpep-kla, respectively). MSLNpep-kla—and, to a lesser extent, MSLNpep-KLA—exhibited selective cytotoxicity toward MSLN-high versus MSLN-low cells. Systemic MSLNpep-kla, but not MSLNpep-KLA, suppressed orthotopic pancreatic tumor growth, increased survival, and produced no detectable hepatic or renal toxicity in mice. MSLNpep-kla also induced cytotoxicity in patient-derived pancreatic cancer organoids proportionate to MSLN expression. Analysis of a public single-cell RNA-sequencing dataset of human pancreatic cancer tissues revealed that MSLN was predominantly expressed in malignant ductal cells while showing negligible expression in normal ductal cells and stromal cells. These findings demonstrate that MSLNpep inhibits tumor-cell migration and enables targeted delivery of therapeutic payloads to MSLN-high pancreatic tumors, supporting its use as a peptide ligand for cancer therapy.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Open AccessMesothelin-Binding Peptide Inhibits Cell Migration and Enables Targeted Delivery of a Mitochondrial-Membrane-Damaging Peptide to Pancreatic Tumors
Mesothelin (MSLN) is up-regulated in many tumors, including pancreatic tumors, making it a promising therapeutic target. We used a phage-displayed peptide library to identify an MSLN-binding peptide. CTILWSLTC, synthesized in cyclic form (MSLNpep), was selected from the library. MSLNpep bound preferentially to MSLN-high versus MSLN-low cells, internalized efficiently, and bound recombinant MSLN more strongly than a control peptide. MSLNpep treatment reduced migration and invasion in MSLN-high tumor cells. To enable targeted cytotoxicity, we generated chimeras linking MSLNpep to L-form or D-form mitochondrial-membrane-damaging peptides (MSLNpep-KLA and MSLNpep-kla, respectively). MSLNpep-kla—and, to a lesser extent, MSLNpep-KLA—exhibited selective cytotoxicity toward MSLN-high versus MSLN-low cells. Systemic MSLNpep-kla, but not MSLNpep-KLA, suppressed orthotopic pancreatic tumor growth, increased survival, and produced no detectable hepatic or renal toxicity in mice. MSLNpep-kla also induced cytotoxicity in patient-derived pancreatic cancer organoids proportionate to MSLN expression. Analysis of a public single-cell RNA-sequencing dataset of human pancreatic cancer tissues revealed that MSLN was predominantly expressed in malignant ductal cells while showing negligible expression in normal ductal cells and stromal cells. These findings demonstrate that MSLNpep inhibits tumor-cell migration and enables targeted delivery of therapeutic payloads to MSLN-high pancreatic tumors, supporting its use as a peptide ligand for cancer therapy.
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
PD-L1/Lag3 Bispecific Immune Checkpoint Blocking Nanocage Exhibits Potent Antitumor Activity beyond Dual Blockade of PD-L1 and Lag3
The therapeutic efficacy of blocking programmed cell death protein 1 and programmed cell death ligand 1 (PD-L1) can be augmented through combination with additional immune checkpoint inhibitors. Lymphocyte-activation gene 3 (Lag3) is an inhibitory checkpoint receptor that contributes to T-cell exhaustion and tumor immune evasion. We hypothesized that cotargeting PD-L1 and Lag3 using a human ferritin nanocage platform could provide an alternative therapeutic strategy to monoclonal antibodies (mAbs) against PD-L1 or Lag3 in modulating antitumor immune responses. Here, we describe a PD-L1/Lag3 bispecific immune checkpoint-blocking ferritin nanocage (P1L2) displaying 24 PD-L1 binding peptides and 24 Lag3 binding peptides on its surface. P1L2 demonstrated simultaneous binding to both PD-L1 and Lag3 and exhibited stronger immune-stimulatory activity than either parent nanocage or mAbs against PD-L1 or Lag3. In a syngeneic mouse colon cancer model, P1L2 specifically targeted tumors and substantially suppressed tumor growth compared with each parent nanocage alone or in combination. Moreover, P1L2 showed more potent antitumor activity than a mAb against PD-L1 or Lag3 alone or in combination. These findings demonstrate that the PD-L1/Lag3 bispecific immune checkpoint-blocking ferritin nanocage is a promising nanomedicine for cancer immunotherapy and has potential applications against various solid tumors.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Open AccessPD-L1/Lag3 Bispecific Immune Checkpoint Blocking Nanocage Exhibits Potent Antitumor Activity beyond Dual Blockade of PD-L1 and Lag3
The therapeutic efficacy of blocking programmed cell death protein 1 and programmed cell death ligand 1 (PD-L1) can be augmented through combination with additional immune checkpoint inhibitors. Lymphocyte-activation gene 3 (Lag3) is an inhibitory checkpoint receptor that contributes to T-cell exhaustion and tumor immune evasion. We hypothesized that cotargeting PD-L1 and Lag3 using a human ferritin nanocage platform could provide an alternative therapeutic strategy to monoclonal antibodies (mAbs) against PD-L1 or Lag3 in modulating antitumor immune responses. Here, we describe a PD-L1/Lag3 bispecific immune checkpoint-blocking ferritin nanocage (P1L2) displaying 24 PD-L1 binding peptides and 24 Lag3 binding peptides on its surface. P1L2 demonstrated simultaneous binding to both PD-L1 and Lag3 and exhibited stronger immune-stimulatory activity than either parent nanocage or mAbs against PD-L1 or Lag3. In a syngeneic mouse colon cancer model, P1L2 specifically targeted tumors and substantially suppressed tumor growth compared with each parent nanocage alone or in combination. Moreover, P1L2 showed more potent antitumor activity than a mAb against PD-L1 or Lag3 alone or in combination. These findings demonstrate that the PD-L1/Lag3 bispecific immune checkpoint-blocking ferritin nanocage is a promising nanomedicine for cancer immunotherapy and has potential applications against various solid tumors.
- Open Access
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Herbmed Pharmacology
- Vol. 13 (1) , 90-100
Magnolia kobus DC leaf ethanol extract alleviated lipopolysaccharide-induced acute lung inflammation by suppressing NF-κB and Nrf2 signaling
Introduction: Magnolia kobus DC has been used as herbal medicine to treat coughs and is known to exert biological effects such as anti-inflammatory, antioxidant, and antibacterial properties. We aimed to define the pharmacological effects of M. kobus leaf ethanol extract (MLEE) on acute lung inflammation and explore the underlying mechanisms of action. Methods: For in vitro investigations, RAW 264.7 cells were pretreated with MLEE (1, 10, and 100 μg/mL) and stimulated with lipopolysaccharide (LPS). For in vivo investigations, BALB/c mice were intratracheally administered with LPS for 24 hours after injection of MLEE (0.3, 3, and 30 mg/kg). Hematoxylin and eosin staining was used for histopathology analysis of lung tissue. The phytochemical constituents of MLEE were analyzed using high-performance liquid chromatography. Results: In RAW 264.7 cells, MLEE reduced the activation of the inflammatory mediators (inducible nitric oxide synthase and cyclooxygenase-2) and the nuclear translocation of nuclear factor (NF)-κB and nuclear factor erythroid-2-related factor 2 (Nrf2). The intraperitoneal injection of MLEE (30 mg/kg) attenuated interstitial edema and immune cell infiltration in LPS-induced acute lung inflammation. MLEE also inhibited the activation of cyclooxygenase-2, NF-κB, and Nrf2 in the lung tissue. Conclusion: Taken together, MLEE exerted an anti-inflammatory effect by inhibiting inflammatory and oxidative mediators on acute lung inflammation suggesting that it might be used as a natural drug for treating acute lung inflammatory diseases.
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Herbmed Pharmacology
- Vol. 13 (1) , 90-100
Open AccessMagnolia kobus DC leaf ethanol extract alleviated lipopolysaccharide-induced acute lung inflammation by suppressing NF-κB and Nrf2 signaling
Introduction: Magnolia kobus DC has been used as herbal medicine to treat coughs and is known to exert biological effects such as anti-inflammatory, antioxidant, and antibacterial properties. We aimed to define the pharmacological effects of M. kobus leaf ethanol extract (MLEE) on acute lung inflammation and explore the underlying mechanisms of action. Methods: For in vitro investigations, RAW 264.7 cells were pretreated with MLEE (1, 10, and 100 μg/mL) and stimulated with lipopolysaccharide (LPS). For in vivo investigations, BALB/c mice were intratracheally administered with LPS for 24 hours after injection of MLEE (0.3, 3, and 30 mg/kg). Hematoxylin and eosin staining was used for histopathology analysis of lung tissue. The phytochemical constituents of MLEE were analyzed using high-performance liquid chromatography. Results: In RAW 264.7 cells, MLEE reduced the activation of the inflammatory mediators (inducible nitric oxide synthase and cyclooxygenase-2) and the nuclear translocation of nuclear factor (NF)-κB and nuclear factor erythroid-2-related factor 2 (Nrf2). The intraperitoneal injection of MLEE (30 mg/kg) attenuated interstitial edema and immune cell infiltration in LPS-induced acute lung inflammation. MLEE also inhibited the activation of cyclooxygenase-2, NF-κB, and Nrf2 in the lung tissue. Conclusion: Taken together, MLEE exerted an anti-inflammatory effect by inhibiting inflammatory and oxidative mediators on acute lung inflammation suggesting that it might be used as a natural drug for treating acute lung inflammatory diseases.
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in Theranostics
- Vol. 14 (6) , 2605-2621
IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis
Rationale: Nab-paclitaxel (Abx) is widely employed in malignant tumor therapy. In tumor cells and pro-tumoral M2-type macrophages, the IL4 receptor (IL4R) is upregulated. This study aimed to elucidate the selective delivery of Abx to M2-type macrophages by targeting IL4R and reprogramming them into an anti-tumoral M1-type.
- 1 January 2024
- Published by Ivyspring International Publisher in Theranostics
- Vol. 14 (6) , 2605-2621
Open AccessIL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis
Rationale: Nab-paclitaxel (Abx) is widely employed in malignant tumor therapy. In tumor cells and pro-tumoral M2-type macrophages, the IL4 receptor (IL4R) is upregulated. This study aimed to elucidate the selective delivery of Abx to M2-type macrophages by targeting IL4R and reprogramming them into an anti-tumoral M1-type.
- Open Access
- 27 December 2023
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (1) , 575-587
Immune Checkpoint-Blocking Nanocages Cross the Blood–Brain Barrier and Impede Brain Tumor Growth
Glioblastoma (GBM) is the deadliest tumor of the central nervous system, with a median survival of less than 15 months. Despite many trials, immune checkpoint-blocking (ICB) therapies using monoclonal antibodies against the PD-1/PD-L1 axis have demonstrated only limited benefits for GBM patients. Currently, the main hurdles in brain tumor therapy include limited drug delivery across the blood-brain barrier (BBB) and the profoundly immune-suppressive microenvironment of GBM. Thus, there is an urgent need for new therapeutics that can cross the BBB and target brain tumors to modulate the immune microenvironment. To this end, we developed an ICB strategy based on the BBB-permeable, 24-subunit human ferritin heavy chain, modifying the ferritin surface with 24 copies of PD-L1-blocking peptides to create ferritin-based ICB nanocages. The PD-L1pep ferritin nanocages first demonstrated their tumor-targeting and antitumor activities in an allograft colon cancer model. Next, we found that these PD-L1pep ferritin nanocages efficiently penetrated the BBB and targeted brain tumors through specific interactions with PD-L1, significantly inhibiting tumor growth in an orthotopic intracranial tumor model. The addition of PD-L1pep ferritin nanocages to triple in vitro cocultures of T cells, GBM cells, and glial cells significantly inhibited PD-1/PD-L1 interactions and restored T-cell activity. Collectively, these findings indicate that ferritin nanocages displaying PD-L1-blocking peptides can overcome the primary hurdle of brain tumor therapy and are, therefore, promising candidates for treating GBM.
- 27 December 2023
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (1) , 575-587
Open AccessImmune Checkpoint-Blocking Nanocages Cross the Blood–Brain Barrier and Impede Brain Tumor Growth
Glioblastoma (GBM) is the deadliest tumor of the central nervous system, with a median survival of less than 15 months. Despite many trials, immune checkpoint-blocking (ICB) therapies using monoclonal antibodies against the PD-1/PD-L1 axis have demonstrated only limited benefits for GBM patients. Currently, the main hurdles in brain tumor therapy include limited drug delivery across the blood-brain barrier (BBB) and the profoundly immune-suppressive microenvironment of GBM. Thus, there is an urgent need for new therapeutics that can cross the BBB and target brain tumors to modulate the immune microenvironment. To this end, we developed an ICB strategy based on the BBB-permeable, 24-subunit human ferritin heavy chain, modifying the ferritin surface with 24 copies of PD-L1-blocking peptides to create ferritin-based ICB nanocages. The PD-L1pep ferritin nanocages first demonstrated their tumor-targeting and antitumor activities in an allograft colon cancer model. Next, we found that these PD-L1pep ferritin nanocages efficiently penetrated the BBB and targeted brain tumors through specific interactions with PD-L1, significantly inhibiting tumor growth in an orthotopic intracranial tumor model. The addition of PD-L1pep ferritin nanocages to triple in vitro cocultures of T cells, GBM cells, and glial cells significantly inhibited PD-1/PD-L1 interactions and restored T-cell activity. Collectively, these findings indicate that ferritin nanocages displaying PD-L1-blocking peptides can overcome the primary hurdle of brain tumor therapy and are, therefore, promising candidates for treating GBM.
- Top Cited PapersOpen Access
- 1 June 2023
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 55 (6) , 1099-1109
Peptides as multifunctional players in cancer therapy
Peptides exhibit lower affinity and a shorter half-life in the body than antibodies. Conversely, peptides demonstrate higher efficiency in tissue penetration and cell internalization than antibodies. Regardless of the pros and cons of peptides, they have been used as tumor-homing ligands for delivering carriers (such as nanoparticles, extracellular vesicles, and cells) and cargoes (such as cytotoxic peptides and radioisotopes) to tumors. Additionally, tumor-homing peptides have been conjugated with cargoes such as small-molecule or chemotherapeutic drugs via linkers to synthesize peptide–drug conjugates. In addition, peptides selectively bind to cell surface receptors and proteins, such as immune checkpoints, receptor kinases, and hormone receptors, subsequently blocking their biological activity or serving as hormone analogs. Furthermore, peptides internalized into cells bind to intracellular proteins and interfere with protein–protein interactions. Thus, peptides demonstrate great application potential as multifunctional players in cancer therapy.
- 1 June 2023
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 55 (6) , 1099-1109
Top Cited PapersOpen AccessPeptides as multifunctional players in cancer therapy
Peptides exhibit lower affinity and a shorter half-life in the body than antibodies. Conversely, peptides demonstrate higher efficiency in tissue penetration and cell internalization than antibodies. Regardless of the pros and cons of peptides, they have been used as tumor-homing ligands for delivering carriers (such as nanoparticles, extracellular vesicles, and cells) and cargoes (such as cytotoxic peptides and radioisotopes) to tumors. Additionally, tumor-homing peptides have been conjugated with cargoes such as small-molecule or chemotherapeutic drugs via linkers to synthesize peptide–drug conjugates. In addition, peptides selectively bind to cell surface receptors and proteins, such as immune checkpoints, receptor kinases, and hormone receptors, subsequently blocking their biological activity or serving as hormone analogs. Furthermore, peptides internalized into cells bind to intracellular proteins and interfere with protein–protein interactions. Thus, peptides demonstrate great application potential as multifunctional players in cancer therapy.
- Open Access
IRF3 Activation in Mast Cells Promotes FcεRI-Mediated Allergic Inflammation
(1) Background: This study aims to elucidate a novel non-transcriptional action of IRF3 in addition to its role as a transcription factor in mast cell activation and associated allergic inflammation; (2) Methods: For in vitro experiments, mouse bone-marrow-derived mast cells (mBMMCs) and a rat basophilic leukemia cell line (RBL-2H3) were used for investigating the underlying mechanism of IRF3 in mast-cell-mediated allergic inflammation. For in vivo experiments, wild-type and Irf3 knockout mice were used for evaluating IgE-mediated local and systemic anaphylaxis; (3) Results: Passive cutaneous anaphylaxis (PCA)-induced tissues showed highly increased IRF3 activity. In addition, the activation of IRF3 was observed in DNP-HSA-treated mast cells. Phosphorylated IRF3 by DNP-HSA was spatially co-localized with tryptase according to the mast cell activation process, and FcεRI-mediated signaling pathways directly regulated that activity. The alteration of IRF3 affected the production of granule contents in the mast cells and the anaphylaxis responses, including PCA- and ovalbumin-induced active systemic anaphylaxis. Furthermore, IRF3 influenced the post-translational processing of histidine decarboxylase (HDC), which is required for granule maturation; and (4) Conclusion: Through this study, we demonstrated the novel function of IRF3 as an important factor inducing mast cell activation and as an upstream molecule for HDC activity.
Open AccessIRF3 Activation in Mast Cells Promotes FcεRI-Mediated Allergic Inflammation
(1) Background: This study aims to elucidate a novel non-transcriptional action of IRF3 in addition to its role as a transcription factor in mast cell activation and associated allergic inflammation; (2) Methods: For in vitro experiments, mouse bone-marrow-derived mast cells (mBMMCs) and a rat basophilic leukemia cell line (RBL-2H3) were used for investigating the underlying mechanism of IRF3 in mast-cell-mediated allergic inflammation. For in vivo experiments, wild-type and Irf3 knockout mice were used for evaluating IgE-mediated local and systemic anaphylaxis; (3) Results: Passive cutaneous anaphylaxis (PCA)-induced tissues showed highly increased IRF3 activity. In addition, the activation of IRF3 was observed in DNP-HSA-treated mast cells. Phosphorylated IRF3 by DNP-HSA was spatially co-localized with tryptase according to the mast cell activation process, and FcεRI-mediated signaling pathways directly regulated that activity. The alteration of IRF3 affected the production of granule contents in the mast cells and the anaphylaxis responses, including PCA- and ovalbumin-induced active systemic anaphylaxis. Furthermore, IRF3 influenced the post-translational processing of histidine decarboxylase (HDC), which is required for granule maturation; and (4) Conclusion: Through this study, we demonstrated the novel function of IRF3 as an important factor inducing mast cell activation and as an upstream molecule for HDC activity.
- Open Access
- 22 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 976196
Epigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p
Reprogramming M2-type, pro-tumoral tumor-associated macrophages (TAMs) into M1-type, anti-tumoral macrophages is a key strategy in cancer therapy. In this study, we exploited epigenetic therapy using the DNA methylation inhibitor 5-aza-2’-deoxycytidine (5-aza-dC) and the histone deacetylation inhibitor trichostatin A (TSA), to reprogram M2-type macrophages into an M1-like phenotype. Treatment of M2-type macrophages with the combination of 5-aza-dC and TSA decreased the levels of M2 macrophage cytokines while increasing those of M1 macrophage cytokines, as compared to the use of either therapy alone. Conditioned medium of M2 macrophages treated with the combination of 5-aza-dC and TSA sensitized the tumor cells to paclitaxel. Moreover, treatment with the combination inhibited tumor growth and improved anti-tumor immunity in the tumor microenvironment. Depletion of macrophages reduced the anti-tumor growth activity of the combination therapy. Profiling of miRNAs revealed that the expression of miR-7083-5p was remarkably upregulated in M2 macrophages, following treatment with 5-aza-dC and TSA. Transfection of miR-7083-5p reprogrammed the M2-type macrophages towards an M1-like phenotype, and adoptive transfer of M2 macrophages pre-treated with miR-7083-5p into mice inhibited tumor growth. miR-7083-5p inhibited the expression of colony-stimulating factor 2 receptor alpha and CD43 as candidate targets. These results show that epigenetic therapy upon treatment with the combination of 5-aza-dC and TSA skews M2-type TAMs towards the M1-like phenotype by upregulating miR-7083-5p, which contributes to the inhibition of tumor growth.
- 22 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 976196
Open AccessEpigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p
Reprogramming M2-type, pro-tumoral tumor-associated macrophages (TAMs) into M1-type, anti-tumoral macrophages is a key strategy in cancer therapy. In this study, we exploited epigenetic therapy using the DNA methylation inhibitor 5-aza-2’-deoxycytidine (5-aza-dC) and the histone deacetylation inhibitor trichostatin A (TSA), to reprogram M2-type macrophages into an M1-like phenotype. Treatment of M2-type macrophages with the combination of 5-aza-dC and TSA decreased the levels of M2 macrophage cytokines while increasing those of M1 macrophage cytokines, as compared to the use of either therapy alone. Conditioned medium of M2 macrophages treated with the combination of 5-aza-dC and TSA sensitized the tumor cells to paclitaxel. Moreover, treatment with the combination inhibited tumor growth and improved anti-tumor immunity in the tumor microenvironment. Depletion of macrophages reduced the anti-tumor growth activity of the combination therapy. Profiling of miRNAs revealed that the expression of miR-7083-5p was remarkably upregulated in M2 macrophages, following treatment with 5-aza-dC and TSA. Transfection of miR-7083-5p reprogrammed the M2-type macrophages towards an M1-like phenotype, and adoptive transfer of M2 macrophages pre-treated with miR-7083-5p into mice inhibited tumor growth. miR-7083-5p inhibited the expression of colony-stimulating factor 2 receptor alpha and CD43 as candidate targets. These results show that epigenetic therapy upon treatment with the combination of 5-aza-dC and TSA skews M2-type TAMs towards the M1-like phenotype by upregulating miR-7083-5p, which contributes to the inhibition of tumor growth.
- Open Access
- 15 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1978
Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer
Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) have been demonstrated to deliver therapeutic drugs in preclinical studies. However, their use is limited, as they lack the ability to specifically deliver drugs to tumor tissues in vivo. In the present study, we propose the use of a targeting peptide, IL-4R-binding peptide (IL4RPep-1), to specifically deliver intravenously (i.v.) infused EVs to thyroid tumors. In vivo, a xenograft tumor model was treated with either the control peptide (NSSSVDK) or IL4RPep-1-Flamma; mice were fluorescently imaged (FLI) using an in vivo imaging system at 0–3 h post-treatment. EVs (labeled with DiD dye) were conjugated with IL4RPep-1 through a DOPE-NHS linker and administered to mice intravenously. FLI was performed 0–24 h post-injection, and the animals were sacrificed for further experiments. The morphology and size of EVs, the presence of EV markers such as CD63 and ALIX, and the absence of the markers GM130 and Cyto-C were confirmed. In vivo, FLI indicated an accumulation of i.v. injected IL4RPep-1-Flamma at the tumor site 90 min post-injection. No accumulation of NSSSVDK-Flamma was detected. In vivo, IL4RPep-1-EVs targeted the Cal-62 tumor 2 h post-injection. NSSSVDK-EVs were not even detected in the tumor 24 h post-injection. The quantification of FLI showed a significant accumulation of MSC-EVs in the tumor 2 h, 3 h, and 24 h post-injection. Furthermore, ex vivo imaging and an IF analysis confirmed the in vivo findings. Our results demonstrate the use of the IL4RPep-1 peptide as a targeting moiety of EVs for IL-4R-expressing anaplastic thyroid tumors.
- 15 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1978
Open AccessInterleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer
Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) have been demonstrated to deliver therapeutic drugs in preclinical studies. However, their use is limited, as they lack the ability to specifically deliver drugs to tumor tissues in vivo. In the present study, we propose the use of a targeting peptide, IL-4R-binding peptide (IL4RPep-1), to specifically deliver intravenously (i.v.) infused EVs to thyroid tumors. In vivo, a xenograft tumor model was treated with either the control peptide (NSSSVDK) or IL4RPep-1-Flamma; mice were fluorescently imaged (FLI) using an in vivo imaging system at 0–3 h post-treatment. EVs (labeled with DiD dye) were conjugated with IL4RPep-1 through a DOPE-NHS linker and administered to mice intravenously. FLI was performed 0–24 h post-injection, and the animals were sacrificed for further experiments. The morphology and size of EVs, the presence of EV markers such as CD63 and ALIX, and the absence of the markers GM130 and Cyto-C were confirmed. In vivo, FLI indicated an accumulation of i.v. injected IL4RPep-1-Flamma at the tumor site 90 min post-injection. No accumulation of NSSSVDK-Flamma was detected. In vivo, IL4RPep-1-EVs targeted the Cal-62 tumor 2 h post-injection. NSSSVDK-EVs were not even detected in the tumor 24 h post-injection. The quantification of FLI showed a significant accumulation of MSC-EVs in the tumor 2 h, 3 h, and 24 h post-injection. Furthermore, ex vivo imaging and an IF analysis confirmed the in vivo findings. Our results demonstrate the use of the IL4RPep-1 peptide as a targeting moiety of EVs for IL-4R-expressing anaplastic thyroid tumors.